Switching from Ticagrelor to Prasugrel in Acute Coronary Syndrome

SWITCH SWEDEHEART was a Phase 4 cluster-randomized trial comparing two already-approved antiplatelet therapies (ticagrelor vs. prasugrel) in acute myocardial infarction patients across seven Swedish regions, finding equivalent or improved care quality at half the medication cost. The trial faced a regulatory challenge when Sweden's Medical Products Agency demanded it be stopped, but courts ruled in favor of the researchers, establishing important legal precedent for pragmatic comparative effectiveness studies. Most available commentary focuses on the legal battle rather than clinical results, with limited outside expert reaction in the source material.

Elmir Omerovic

Professor and senior consultant, Sahlgrenska University Hospital

“We need to know that treatments work in the real world, not just in strictly controlled study environments. This project shows that we can combine the best possible care for patients with a more efficient use of our shared resources.”

BR

Björn Redfors

Professor and senior consultant, Sahlgrenska University Hospital

“The ruling creates security and clarity for researchers and clinical operations that want to evaluate the effect of new treatments in clinical practice in a systematic and scientifically robust way.”

HC

Helena Carrick

Legal counsel, Gothia Forum

“We could not have done it without each other. The researchers contributed deep medical understanding; we were able to translate that into legal arguments the court could assess. This was a true team effort.”